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Background and purpose   Many investigations on biodegradable 
materials acting as an antibiotic carrier for local drug delivery are 
based on poly(lactide). However, the use of poly(lactide) implants 
in bone has been disputed because of poor bone regeneration at 
the site of implantation. Poly(trimethylene carbonate) (PTMC) is 
an enzymatically degradable polymer that does not produce acidic 
degradation products. We explored the suitability of PTMC as an 
antibiotic releasing polymer for the local treatment of osteomy-
elitis. 
Methods   This study addressed 2 separate attributes of PTMC: 
(1) the release kinetics of gentamicin-loaded PTMC and (2) its 
behavior in inhibiting biofilm formation. Both of these character-
istics were compared with those of commercially available gen-
tamicin-loaded poly(methylmethacrylate) (PMMA) beads, which 
are commonly used in the local treatment of osteomyelitis. 
Results   In a lipase solution that mimics the in vivo situation, 
PTMC  discs  with  gentamicin  incorporated  were  degraded  by 
surface erosion and released 60% of the gentamicin within 14 
days. This is similar to the gentamicin release from clinically used 
PMMA  beads.  Moreover,  biofilm  formation  by  Staphylococcus 
aureus was inhibited by approximately 80% over at least 14 days 
in the presence of gentamicin-loaded PTMC discs. This is similar 
to the effect of gentamicin-loaded PMMA beads. In the absence 
of the lipase, surface erosion of PTMC discs did not occur and 
gentamicin release and biofilm inhibition were limited. 
Interpretation      Since  gentamicin-loaded  PTMC  discs  show 
antibiotic release characteristics and biofilm inhibition character-
istics similar to those of gentamicin-loaded PMMA beads, PTMC 
appears to be a promising biodegradable carrier in the local treat-
ment of osteomyelitis.

Osteomyelitis is characterized by progressive inflammatory 
bone destruction (Mader et al. 1997b). In general, chronic 
osteomyelitis  cannot  be  eradicated  solely  by  intravenous 
administration  of  antibiotics  (Haleem  et  al.  2004). As  the 
infected necrotic focus within the bone is often surrounded by 
sclerotic avascular bone, it is almost unreachable using sys-
temic antibiotics. Moreover, the necrotic bone forms a suitable 
substrate for biofilm formation, which reduces the antibiotic 
sensitivity of the infecting pathogens and makes the infection 
difficult to treat (Gristina et al. 1985, Stewart and Costerton 
2001). Thus, in the management of chronic osteomyelitis, it 
is generally necessary to remove the infected bone and tissue 
followed by implantation of an antibiotic delivery system that 
can provide high local antibiotic concentrations for extended 
periods of time.
Sustained  high  local  antibiotic  concentrations  are  cur-
rently  achieved  by  the  implantation  of  gentamicin-loaded 
poly(methylmethacrylate)  (PMMA)  beads.  Although  these 
beads have been used to treat osteomyelitis for many years 
(Buchholz et al. 1984, Klemm 2001), their major drawback is 
the additional surgery required to remove the beads after ther-
apy, as PMMA is not biodegradable. Also, PMMA beads do 
not release all of their gentamicin content: after 2 weeks in situ, 
only 20–70% of the total amount of gentamicin incorporated 
in the beads is released and the gentamicin concentrations in 
serum drop considerably thereafter (Walenkamp et al. 1986). 
Continuous, high release rates for prolonged periods of time 
are necessary, however, as the polymer bead surface itself may 
provide an ideal surface for biofilm formation that inhibits dif-
fusion of antibiotics, leading to recurrent infection (Mader et 
al. 1999, Kanellakopoulou and Giamarellos-Bourboulis 2000, 
Neut et al. 2001, 2003). Incomplete drug release, possible colo-
nization of PMMA beads by bacteria (Neut et al. 2001, 2003), 
and the requirement of surgical removal of these beads have 
prompted investigations on the use of biodegradable materials 
as antibiotic carriers for local delivery, especially for the treat-
ment of osteomyelitis with small volumes of dead space.Acta Orthopaedica 2009; 80 (5): 514–519  515
Currently, the biodegradable carrier materials most often 
investigated have been based on poly(lactide) (PLA) and/or 
poly(glycolide) (PGA) (Lin et al. 1999, Garvin and Feschuk 
2005, Koort et al. 2006, Naraharisetti et al. 2006). Biodegrad-
able carriers can sustain high local antibiotic concentrations 
for up to 8 months, whereas antibiotic release from PMMA 
beads can diminish to values below the detection limit within 
12  days  (Mader  et  al.  1997a).  Furthermore,  biodegradable 
carriers can release all of their antibiotic content (Koort et al. 
2006). 
The use of PLA and PGA implants has been disputed (Barber 
and Dockery 2006, Bergsma et al. 1995, Böstman 1991, Böst-
man et al. 2005). An important issue relates to the biocompati-
bility of these polymers in relation to human bone. There have 
been several studies reporting an inflammatory foreign-body 
reaction, reduced bone regeneration, or increased bone resorp-
tion at the site of implantation when PLA or PGA implants 
were used (Böstman et al. 1990, 2005, Böstman 1991, Guna-
tillake and Adhikari 2003). It has been suggested that acidic 
degradation products and a subsequent decrease in local pH 
are the cause of decreased bone regeneration (Gunatillake and 
Adhikari 2003). Thus, PLA and/or PGA do not appear to be 
the most suitable carriers for use in bone, and further investi-
gation of alternative materials is required.
One possible candidate material is poly(trimethylene car-
bonate) (PTMC), a biodegradable polymer that is relatively 
new in biomedical applications. 
In contrast to PLA/PGA, the degradation products of PTMC 
are not acidic (Zhang et al. 2006). Interestingly, the degradation 
rate of PTMC in vitro at pH 7 and 37°C appears to be quite low 
(Zhu et al. 1991), while the degradation rate of PTMC is much 
faster in vivo (Zhu et al. 1991, Pego et al. 2003, Zhang et al. 
2006). The difference between in vitro and in vivo degradation 
rates suggests that enzymes are involved. Indeed, enzymatic 
degradation of PTMC and TMC co-polymers has been shown 
to occur in vitro (Matsumura et al. 2001, Tsutsumi et al. 2002, 
Zhang et al. 2006). Overall, PTMC has good biocompatibility 
and degrades enzymatically in a uniform manner by surface 
erosion; thus, it may provide sustained high antibiotic release 
rates. This has not been established experimentally. 
The objective of this in vitro study was to explore the suit-
ability of PTMC as a biodegradable, antibiotic-releasing car-
rier, and to compare it with commercially available gentami-
cin-loaded  PMMA  beads. The  study  investigated  2  related 
issues  regarding  gentamicin-loaded  PTMC:  (1)  the  release 
kinetics and (2) its ability to inhibit biofilm formation.
Material and methods
Materials
Polymer-grade 1,3-trimethylene carbonate (TMC) was pur-
chased  from  Boehringer  Ingelheim  (Ingelheim,  Germany). 
Gentamicin sulfate was purchased from Sigma-Aldrich (St. 
Louis,  MO),  and  analytical-grade  chloroform  and  diethyl 
ether  were  purchased  from  Merck  BV  (Schiphol-Rijk,  the 
Netherlands).  A  lipase  solution  from  Thermomyces  lanu-
ginosus (EC 3.1.1.3., minimum 105 units/g) was purchased 
from Sigma-Aldrich and used as received. Antibiotic-loaded 
poly(methylmethacrylate) (PMMA) beads are commercially 
available under the name Septopal (Biomet Europe, Darm-
stadt, Germany). Each Septopal bead (diameter: 7 mm) con-
tains 7.5 mg of gentamicin sulfate (corresponding to 4.5 mg 
of gentamicin base). Staphylococcus aureus 0734 (MIC-value 
of gentamicin amounts to 0.50 µg/mL) is one of the most com-
monly involved bacterial strains in osteomyelitis (Lew and 
Waldvogel 2004) and was retrieved from an infected prosthe-
sis.
Preparation of gentamicin-loaded PTMC
High-molecular-weight  PTMC  (Mn  =  388  ×  103  g/mol) 
was  synthesized,  purified,  and  characterized  as  previously 
described (Zhang et al. 2006). 2 solutions of PTMC in chloro-
form were prepared (4% w/v). Gentamicin sulfate (10% w/w 
with respect to the polymer) was added to one of the solutions 
and mixed for 5 min using an ultrasonic bath, followed by 
extensive stirring for 24 h. This suspension was then dropped 
into an excess of diethyl ether. As PTMC and gentamicin sul-
fate do not dissolve in diethyl ether, this induces precipitation 
of the polymer—through which gentamicin is homogeneously 
distributed. The second solution of PTMC in chloroform was 
also precipitated in diethyl ether, but it did not contain genta-
micin sulfate. 
PTMC precipitates with and without gentamicin were com-
pression-molded at 50°C into films of 500 µm thickness using 
a laboratory press. Finally, discs with a diameter of 5 mm were 
punched out of the films. 
Scanning electron microscopy (SEM)
The surface erosion of gentamicin-loaded PTMC was visu-
alized using SEM. A series of SEM micrographs of PTMC 
discs were taken after immersion in phosphate-buffered saline 
(PBS), pH 7.0, or in the lipase solution. After 3, 7, and 10 
days, discs were taken out of the solutions for SEM evaluation. 
Discs were sputter-coated with gold/palladium and examined 
at 2.0 kV in a JEOL field emission scanning electron micro-
scope type 6301F. 
Release of gentamicin
Gentamicin release was determined at 37°C in PBS (in the 
absence of lipase) and in a lipase solution, which induces 
surface erosion of PTMC (Zhang et al. 2006). 3 gentamicin-
loaded PTMC discs were each immersed in 10 mL PBS or 
lipase solution and incubated at 37°C for 2 weeks. Liquid 
samples (500 µL) from both solutions were taken at 6, 24, 
48, 72, 168, and 336 h and stored at 4°C before analysis. For 
comparison, the gentamicin release from gentamicin-loaded 
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Gentamicin concentrations were measured using a proce-
dure described by Zhang et al. (1994). Briefly, an o-phtaldial-
dehyde reagent was made and stored for 24 h in a dark envi-
ronment. A gentamicin-containing aliquot, o-phtaldialdehyde 
reagent, and isopropanol were mixed in equal proportions 
and stored for 30 min at room temperature. Upon reaction 
of o-phtaldialdehyde with the amino groups of gentamicin, 
chromophoric  products  were  obtained.  Their  absorbances 
were measured at 332 nm using a Spectronic 20 Genesys 
spectrophotometer (Spectronic Instruments, Inc. Rochester, 
NY). After measuring the absorbances of a series of solutions 
of known gentamicin concentrations to prepare a calibration 
curve, the absorbance could be related to the gentamicin con-
centration of each aliquot.
 Gentamicin concentrations in lipase solutions could not 
be determined spectrophotometrically due to interference of 
the enzyme. An indirect bacterial inhibition assay, described 
and validated by Joosten et al. (2005), was therefore used to 
determine gentamicin concentrations in the lipase samples. 
Tryptone  soya  broth  (TSB;  Oxoid,  Basingstoke,  UK)  agar 
plates  were  smeared  with  the  S.  aureus  strain.  From  each 
lipase sample and gentamicin solution of known concentra-
tion, 15 µL was dropped onto a TSB agar plate; the plates 
were then incubated at 37°C for 24 h. The antimicrobial agent 
in the samples inhibited bacterial growth during incubation, 
which resulted in zones of inhibition. The areas of the inhibi-
tion zones were measured after incubation, from which the 
gentamicin concentration was deduced by comparison with 
the inhibition zones corresponding to the known gentamicin 
concentrations. 
Inhibition of biofilm formation
The extent to which the released amount of antibiotics inhibits 
the formation of a biofilm is an index of the efficacy of the 
antibiotic-loaded carrier. To study biofilm formation, 2 types 
of bacterial growth media were prepared: TSB and a 4:1 mix-
ture of TSB and lipase solution to allow enzymatic degrada-
tion of PTMC. 3 non-loaded PTMC discs and 3 gentamicin-
loaded PTMC discs were immersed in 10 mL TSB or 10 mL 
TSB/lipase medium for 2 weeks at 37°C. In addition, 3 genta-
micin-loaded PMMA beads were immersed in 10 mL of TSB. 
Medium was collected and replaced with new medium after 
24, 48, 72, 144, 168, 312, and 336 h to obtain samples con-
taining the antibiotic released during the first, second, third, 
seventh, and fourteenth day. 
These elution media were used for the formation of S. aureus 
biofilms in 96-well plates (Nunc-Immuno 96 microwell plates; 
Thermo Fisher Scientific) under stationary conditions. 2 µL 
of bacterial inoculum (approximately 1 × 106 CFU/µL) was 
added to wells containing 198 µL of TSB. After 24 h of incu-
bation at 37°C, the medium was removed and the plates were 
washed 3 times with 220 µL of PBS. Subsequently, each well 
was stained with 200 µL of 1% (w/v) crystal violet in water for 
30 min. After staining, the plates were gently rinsed 3 times 
with demineralized water. Quantitative analysis of biofilm for-
mation was performed by adding 200 µL of ethanol/acetone 
(80:20) to solubilize the crystal violet. The absorbance of this 
crystal violet solution was measured using a FLUOstar Optima 
plate reader (BMG Labtech GmbH, Offenburg, Germany) at a 
wavelength of 575 nm. The absorbance (A) is proportional to 
the amount of crystal violet, which is directly proportional to 
the amount of biofilm grown in each well. 
The maximal amount of biofilm formation was defined as 
the amount grown in elution media collected from non-loaded 
PTMC discs, and the percentage of biofilm inhibition was cal-
culated according to the following equation:
   (A575 loaded PTMC – Aunloaded PTMC)
biofilm inhibition =     × 100
  Aunloaded PTMC 
For gentamicin-loaded PMMA beads, the maximal amount 
of  biofilm  formation  was  defined  as  the  amount  grown  in 
freshly inoculated TSB medium, as non-loaded PMMA beads 
are not commercially available. All experiments included 6 
replicate wells and were performed in triplicate with sepa-
rately cultured bacteria.
Statistics
In evaluating gentamicin release characteristics and inhibition 
of biofilm formation, Student’s t-test for independent samples 
was used. A 95% (p < 0.05, two-tailed) confidence interval 
was applied for statistical significance.
Results    
Scanning electron microscopy
The  surface  topographies  of  PTMC  immersed  for  3,  7,  or 
10 days in PBS and in lipase solution were visualized with 
SEM. Examples of micrographs after immersion for 7 days 
are shown in Figure 1. In PBS, PTMC showed no signs of deg-
radation (Figure 1B), as the surface topography looked exactly 
the same as prior to immersion (Figure 1A) irrespective of the 
number of days the specimens were immersed. In contrast, 
PMTC in lipase solution clearly showed surface erosion of 
the polymer after 7 days, (Figure 1C). This was also observed 
after 3 or 10 days of immersion (micrographs not shown). 
Gentamicin release
The cumulative release of gentamicin from PTMC discs in 
PBS, PTMC discs in lipase solution, and PMMA beads in 
PBS is shown graphically in Figure 2 and numerically in the 
Appendix (see supplementary data), together with detailed sta-
tistical analyses. PTMC in PBS released about 10% of its total 
load within 2 weeks, while PMMA released about 60%. The 
release of gentamicin from PTMC in lipase was more rapid 
than the release of gentamicin from PTMC in PBS (p < 0.05). 
In lipase solution, PTMC discs released approximately 60% of 
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from PTMC with a degrading surface was similar to that of the 
gentamicin-loaded PMMA beads. 
Inhibition of biofilm formation
The biofilm inhibition after 24 h in growth medium containing 
gentamicin released from gentamicin-loaded PTMC discs and 
PMMA beads during the first, second, third, seventh, and four-
teenth day is graphically presented in Figure 3 and numeri-
cally in the Appendix (see supplementary data), together with 
detailed statistical analyses. During the first day of release 
in  growth  medium,  similar  inhibition  by  PTMC  discs  and 
PMMA beads was seen (approximately 80%). However, after 
the first day of release, PTMC in growth medium with no 
lipase showed less biofilm inhibition than that obtained with 
PMMA beads.
The  inhibition  obtained  from  gentamicin-loaded  PTMC 
discs  incubated  in  lipase-containing  growth  medium  was, 
however, better than that obtained with similar discs incubated 
in growth medium only (p < 0.05). After surface erosion in 
the lipase enzyme solution, gentamicin-loaded PTMC showed 
continuous, effective inhibition of biofilm formation (Figure 
3) similar to that obtained with the PMMA beads. 
Figure 1. Scanning electron micrographs of the surface of PTMC discs prior to immersion (A), after immersion in PBS for 7 days (B), and after 
immersion in lipase solution for 7 days (C). The bar represents 10 µm.
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Figure 2. Cumulative gentamicin release from PTMC discs in lipase 
solutions (red circles) and from PTMC discs (blue circles) and Septo-
pal beads (green squares) in PBS as a function of time. The amount 
of gentamicin released is expressed as a percentage of the amount of 
gentamicin incorporated per disc or bead. The error bars indicate the 
standard deviation of 3 experiments performed in each group. 
Figure 3. Inhibition of S. aureus biofilm formation after 24-h release of 
gentamicin in TSB or TSB/lipase medium by gentamicin-loaded PTMC 
discs and Septopal beads after 1, 2, 3, 7, and 14 days. The extent 
of inhibition is expressed relative to non-loaded PTMC (100%). The 
bars represent the means of 3 separate experiments, with the standard 
deviation shown by the error bars. 518  Acta Orthopaedica 2009; 80 (5): 514–519
Discussion 
Gentamicin-loaded PMMA beads constitute an effective drug 
delivery  system  for  local  antibiotic  therapy  in  bone  infec-
tions. However, after high initial gentamicin concentrations at 
the site of the infection, the gentamicin concentrations drop 
considerably (Walenkamp et al. 1986). The main efficacy of 
gentamicin is therefore immediately after implantation of the 
beads, and long-term implantation of the beads is of no value 
in combatting infection. One of the drawbacks of the use of 
non-biodegradable vehicles for local antibiotic delivery (such 
as PMMA beads) is the possible bacterial colonization of their 
surfaces, and biofilm formation. In this respect, biodegradable 
polymers as carriers of antibiotics that degrade by surface ero-
sion may be preferred, as they do not show long-term release 
of sub-inhibitory antibiotic concentrations. Moreover, a bio-
film is perhaps not as easily formed on a material whose sur-
face is undergoing erosion, as the adhering organisms are shed 
continuously along with the eroding material.
PTMC is such a surface-eroding polymer. It is an aliphatic 
polycarbonate, and upon degradation of the carbonate link-
ages by hydrolysis, carbon dioxide and 1,3-propanediol will 
be formed. Thus, PTMC degrades without the formation of 
acidic degradation products and has good compatibility with 
bone tissue. Subcutaneous implantation of PTMC discs in rats 
showed a mild-to-moderate tissue reaction around the implant 
(Pego et al. 2003). Within 1 year, the polymer was completely 
resorbed and the tissue at the site of implantation had regener-
ated. Implantation of PTMC rods into the femur and tibia of 
rabbits gave similar results (Zhang et al. 2006). 
PTMC  degrades  very  slowly  by  hydrolysis  in  vitro:  the 
polymer is stable in water and in buffered solutions (Zhang et 
al. 2006). However, in vivo degradation of PTMC subcutane-
ously implanted in the back of rats was found to be strikingly 
rapid. The mass of 600-µm thick PTMC samples decreased 
linearly with time and resorption was nearly complete in 3 
weeks (Pego et al. 2003). The difference between the in vitro 
and in vivo degradation behavior suggests that enzymes are 
involved in the process, but the specific enzymes involved still 
have to be identified. Zhang et al. (2006) were able to mimic 
the in vivo enzymatic degradation of PTMC using lipase solu-
tions. 
Interestingly, the degradation of PTMC showed character-
istics of a surface erosion process—as the loss of mass could 
be correlated to the decrease in thickness of the specimen, and 
the decrease in molecular weight was limited (Zhu et al. 1991, 
Pego et al. 2003, Zhang et al. 2006). This indicates that con-
trary to the bulk degradation process observed in the case of 
PLA and PGA, the degradation of PTMC mainly takes place 
at the surface of the specimen. In drug delivery applications, 
a surface-eroding polymer may have advantages over a bulk 
eroding polymer, as surface erosion allows constant and con-
trollable drug release rates and the drug is not exposed to the 
environment until the moment it is released.
A crucial point in the treatment of chronic osteomyelitis is 
the handling of the dead space and gentamicin-loaded PMMA 
beads can be used to treat the dead space problem. In addition 
to providing local delivery of antibiotics, these beads will fill 
the dead space. After the infection is cured, the beads can be 
removed and the dead space can be filled either with a bone 
graft or a muscle flap. A specific dead space problem is related 
to  two-stage  revision  of  infected  joint  prostheses.  In  these 
cases, PMMA beads have been used to fill the dead space, 
i.e. to facilitate the implantation of a new prosthesis. In the 
examples above, the surgeon uses PMMA beads as non-bio-
degradable carriers of antibiotics. Accordingly, the use of bio-
degradable carriers is confined to cases where the dead space 
problem is considered to be small. 
The aim of our study was to explore the suitability of bio-
degradable antibiotic-loaded PTMC discs in the local treat-
ment of osteomyelitis, especially for cases where the volume 
of dead space is low. In buffer, PTMC released only small 
amounts of antibiotics during the first 2 weeks, but in a lipase 
solution (where PTMC degrades by surface erosion), this was 
accompanied by a high rate of release of antibiotics similar 
to that observed for non-biodegradable Septopal beads made 
from  PMMA.  In  line  with  this,  gentamicin-loaded  PTMC 
showed less inhibition of biofilm formation for 2 weeks under 
non-surface eroding conditions in buffer than under surface-
eroding conditions in lipase solution. Moreover, the inhibitory 
effect of gentamicin-loaded PTMC in the lipase enzyme solu-
tion was similar to that of clinically used Septopal beads. This 
indicates that under conditions that favor surface degradation 
of the PTMC discs, the polymer could be a suitable biodegrad-
able carrier of antibiotics in the treatment of osteomyelitis. It 
should be emphasized, however, that a strict comparison of 
the antibiotic release behavior of Septopal beads and of our 
PTMC specimens is not possible due to their different geom-
etries, masses, and degrees of gentamicin loading. 
In  this  study,  macroscopic  examination  showed  that  the 
PTMC discs were completely resorbed within 2 weeks upon 
immersion in the lipase solution. As PTMC degrades by a 
surface erosion process, it is possible to extend the degrada-
tion time by increasing the thickness of the specimens and by 
reducing the surface-to-volume ratio. It has also been shown 
that reducing the initial molecular weight of PTMC polymer 
has the effect of reducing the rate of degradation (Zhang et al. 
2006). After implantation for 8 weeks in the femur and tibia 
of rabbits, the mass loss of high molecular weight PTMC457 
rods (60 wt%) was 3 times higher than that of intermediate 
molecular weight PTMC89 rods (20 wt%). Thus, the antibi-
otic release characteristics of gentamicin-loaded PTMC can 
be readily fine-tuned to meet clinical demands.
A next step would be to initiate animal experiments to con-
firm the release characteristics and antimicrobial efficacy of 
gentamicin-loaded PTMC discs as seen in this study. Animal 
experiments should also be carried out to study the long-term 
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tion of bone. This is necessary to ensure that PTMC is safe 
during its degradation in bone, and that it can be used as a drug 
delivery device in orthopedic applications. 
In summary, gentamicin-loaded PTMC discs degrading in 
lipase solution showed antibiotic release kinetics and biofilm 
inhibition properties that are comparable to those of non-bio-
degradable gentamicin-loaded PMMA beads. The use of anti-
biotic-loaded PTMC discs does not require a second surgery 
for the removal of the beads after therapy; therefore, PTMC-
based materials appear to be promising alternative antibiotic 
carriers for the local treatment of osteomyelitis. 
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